Alexion Pharmaceuticals (ALXN) Stock Rating Reaffirmed by Credit Suisse Group

Alexion Pharmaceuticals (NASDAQ:ALXN)‘s stock had its “outperform” rating reissued by analysts at Credit Suisse Group in a research note issued on Thursday. They presently have a $147.00 target price on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective would indicate a potential upside of 21.44% from the stock’s previous close.

Several other equities analysts also recently commented on ALXN. Leerink Swann restated a “buy” rating and set a $182.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, September 25th. Zacks Investment Research downgraded Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Piper Jaffray Companies reiterated an “overweight” rating and issued a $170.00 price objective on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Stifel Nicolaus cut their price objective on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a research report on Tuesday, October 24th. Finally, Royal Bank of Canada lifted their price objective on Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $153.10.

Alexion Pharmaceuticals (ALXN) traded up $0.70 on Thursday, reaching $121.05. The company’s stock had a trading volume of 1,796,046 shares, compared to its average volume of 2,110,000. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34. The firm has a market cap of $27,200.00, a price-to-earnings ratio of 54.04, a P/E/G ratio of 1.01 and a beta of 1.17.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company had revenue of $859.00 million during the quarter, compared to the consensus estimate of $864.34 million. During the same quarter last year, the company earned $1.23 EPS. The company’s quarterly revenue was up 7.5% on a year-over-year basis. equities research analysts expect that Alexion Pharmaceuticals will post 4.82 EPS for the current year.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 2,553 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now owns 36,172 shares of the company’s stock, valued at $4,399,600.36. The sale was disclosed in a document filed with the SEC, which is available through this link. 4.35% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Alexion Pharmaceuticals by 2.2% during the second quarter. Vanguard Group Inc. now owns 14,785,831 shares of the biopharmaceutical company’s stock worth $1,798,992,000 after buying an additional 318,375 shares in the last quarter. State Street Corp grew its position in Alexion Pharmaceuticals by 5.0% during the second quarter. State Street Corp now owns 11,860,647 shares of the biopharmaceutical company’s stock worth $1,443,099,000 after buying an additional 561,962 shares in the last quarter. Ameriprise Financial Inc. grew its position in Alexion Pharmaceuticals by 3.5% during the third quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock worth $896,491,000 after buying an additional 215,005 shares in the last quarter. Jennison Associates LLC grew its position in Alexion Pharmaceuticals by 720.0% during the third quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after buying an additional 4,682,336 shares in the last quarter. Finally, Northern Trust Corp grew its position in Alexion Pharmaceuticals by 17.2% during the second quarter. Northern Trust Corp now owns 2,966,636 shares of the biopharmaceutical company’s stock worth $360,950,000 after buying an additional 435,482 shares in the last quarter. 94.27% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Alexion Pharmaceuticals (ALXN) Stock Rating Reaffirmed by Credit Suisse Group” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://stocknewstimes.com/2018/01/20/alexion-pharmaceuticals-alxn-stock-rating-reaffirmed-by-credit-suisse-group.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply